WP 6: Immune monitoring and biomarker identification to determine immunological efficacy of HEPAVAC
The goal of WP6 is an extensive immune monitoring of patients to determine the immunological efficacy (proof of concept) of the HEPAVAC vaccination strategy in the phase I/II clinical trial. Thereby knowledge about the mechanism-of-action of cancer vaccines will be largely improved. Furthermore new biological markers potentially influencing treatment efficacy in patients and surrogates for vaccine efficacy will be identified.
Leader: Sarah Kutscher, IMM